1. Home
  2. CORT vs KNX Comparison

CORT vs KNX Comparison

Compare CORT & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CORT
  • KNX
  • Stock Information
  • Founded
  • CORT 1998
  • KNX 1989
  • Country
  • CORT United States
  • KNX United States
  • Employees
  • CORT N/A
  • KNX N/A
  • Industry
  • CORT Biotechnology: Pharmaceutical Preparations
  • KNX Trucking Freight/Courier Services
  • Sector
  • CORT Health Care
  • KNX Industrials
  • Exchange
  • CORT Nasdaq
  • KNX Nasdaq
  • Market Cap
  • CORT 7.5B
  • KNX 7.2B
  • IPO Year
  • CORT N/A
  • KNX 1994
  • Fundamental
  • Price
  • CORT $72.98
  • KNX $47.34
  • Analyst Decision
  • CORT Strong Buy
  • KNX Buy
  • Analyst Count
  • CORT 4
  • KNX 17
  • Target Price
  • CORT $142.00
  • KNX $54.06
  • AVG Volume (30 Days)
  • CORT 1.6M
  • KNX 2.7M
  • Earning Date
  • CORT 07-28-2025
  • KNX 07-23-2025
  • Dividend Yield
  • CORT N/A
  • KNX 1.52%
  • EPS Growth
  • CORT 8.36
  • KNX 37.21
  • EPS
  • CORT 1.14
  • KNX 0.93
  • Revenue
  • CORT $685,446,000.00
  • KNX $7,411,973,000.00
  • Revenue This Year
  • CORT $35.83
  • KNX $3.04
  • Revenue Next Year
  • CORT $35.24
  • KNX $6.68
  • P/E Ratio
  • CORT $63.26
  • KNX $50.83
  • Revenue Growth
  • CORT 30.93
  • KNX 1.16
  • 52 Week Low
  • CORT $29.42
  • KNX $36.69
  • 52 Week High
  • CORT $117.33
  • KNX $61.51
  • Technical
  • Relative Strength Index (RSI)
  • CORT 49.68
  • KNX 66.09
  • Support Level
  • CORT $68.52
  • KNX $43.75
  • Resistance Level
  • CORT $75.95
  • KNX $45.09
  • Average True Range (ATR)
  • CORT 2.66
  • KNX 1.19
  • MACD
  • CORT -0.13
  • KNX 0.37
  • Stochastic Oscillator
  • CORT 42.13
  • KNX 96.06

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: